|
Walker, Cheryl L (2002) Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res 57:277-94
|
|
Burroughs, K D; Howe, S R; Okubo, Y et al. (2002) Dysregulation of IGF-I signaling in uterine leiomyoma. J Endocrinol 172:83-93
|
|
Houston, K D; Hunter, D S; Hodges, L C et al. (2001) Uterine leiomyomas: mechanisms of tumorigenesis. Toxicol Pathol 29:100-4
|
|
Hunter, D S; Hodges, L C; Eagon, P K et al. (2000) Influence of exogenous estrogen receptor ligands on uterine leiomyoma: evidence from an in vitro/in vivo animal model for uterine fibroids. Environ Health Perspect 108 Suppl 5:829-34
|
|
Burroughs, K D; Fuchs-Young, R; Davis, B et al. (2000) Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol Reprod 63:1322-30
|
|
Walker, C L; Burroughs, K D; Davis, B et al. (2000) Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig 7:249-56
|
|
Gamage, S D; Bischoff, E D; Burroughs, K D et al. (2000) Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J Pharmacol Exp Ther 295:677-81
|
|
Hunter, D S; Hodges, L C; Vonier, P M et al. (1999) Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium. Cancer Res 59:3090-9
|
|
Johnson, D G; Walker, C L (1999) Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39:295-312
|
|
Howe, S R; Everitt, J L; Gottardis, M M et al. (1997) Rodent model of reproductive tract leiomyomata: characterization and use in preclinical therapeutic studies. Prog Clin Biol Res 396:205-15
|
Showing the most recent 10 out of 12 publications
